Milani 1995.

Methods	4‐week single‐blind placebo run‐in period 4‐week before and after trial
Participants	20 men and women with type IIa primary hypercholesterolaemia age 53 years LDL‐C ≥ 160 mg/dL (4.14 mmol/L) Triglycerides ≤ 250 mg/dL (2.82 mmol/L) exclusion criteria: secondary forms of dyslipidaemia, obesity, abnormal liver or renal function, patients with neoplasms, acute MI, coronary bypass surgery Fluvastatin 40 mg/day baseline TC : 7.6 mmol/L (294 mg/dL) Fluvastatin 40 mg/day baseline LDL‐C : 5.5 mmol/L (213 mg/dL) Fluvastatin 40 mg/day baseline HDL‐C : 1.1 mmol/L (42.5 mg/dL) Fluvastatin 40 mg/day baseline triglycerides: 2.1 mmol/L (186 mg/dL)
Interventions	40 mg/day fluvastatin for 4 weeks 40 mg/day pravastatin for 4 weeks
Outcomes	per cent change from baseline at 4 weeks of plasma TC, LDL‐C, HDL‐C and triglycerides
Source of Funding	unknown
Notes	40 mg/day pravastatin for 4 weeks group was not analysed SDs were imputed by the method of Furikawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before and after design
Allocation concealment (selection bias)	High risk	Controlled before and after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	Not a blinded trial WDAEs were not reported compared to placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported